The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
A NEW ANALYSIS OF ALLOGENEIC INTERACTIONS
Abstract
Summary: Allogeneic reactions have conventionally been considered as typical immune responses by one population of cells to antigens present on the other. This view is inadequate, since it does not explain many features of these reactions, among which are: (1) reactivity is much higher between different strains within a species than between species, in spite of the much greater antigenic disparity in the second case; (2) a very high proportion of cells may respond to allogeneic stimuli; (3) major histocompatibility differences are not essential for vigorous allogeneic reactions; (4) the responding population need not be immunologically competent to respond to antigens of the stimulating population; (5) the stimulating population must be both metabolically active and immunocompetent. We have tried to produce a model of cell interaction which will account for these and other anomalies, while at the same time explaining both normal antigenic stimulation (through cell‐cell cooperation) and allogeneic interactions as examples of the same basic mechanism. The model is based on the Bretscher‐Cohn scheme of cell interaction. An allogeneic reaction is seen as having two stages: (1) Cells come together when antibody receptors on cells of one population combine with antigens on cells of the other. To this extent, our model is the same as the conventional one. It need not be the responding population which has the receptors, however. (2) A species‐specific proliferation signal passes between the cells. This is the same signal as is involved in normal antibody induction. Even antigen‐receptor bonds which are very weak may result in effective stimulation of one or both partners because of enhancing effect of this signal, and because the antigens involved are probably repeated over the cell surface, enabling multipoint binding. This explains the very high proportions of cells which proliferate. The exact outcome of any allogeneic interaction will depend on which of the two populations have antibody receptors for antigens on the other, which can produce the proliferative stimulus, and which can respond to either the proliferative signal alone or to this stimulus plus antigen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,692
Immunogenetic and Biological Aspects of in Vitro Lymphocyte Allotransformation (MLR) in the Mouse
Festenstein, H. (1973) · Immunological Reviews · doi:10.1111/j.1600-065x.1973.tb00111.x · Cited by 161
Inability of UV-Irradiated Lymphocytes to Stimulate Allogeneic Cells in Mixed Lymphocyte Culture
Lindahl‐Kiessling, K., & Säfwenberg, J. (2009) · International Archives of Allergy and Applied Immunology · doi:10.1159/000230559 · Cited by 112
Allogeneic stimulation modulates the in vitro response of T cells to transplantation antigen
Lafferty, K. J., MISKO, I. S., & Cooley, M. A. (1974) · Nature · doi:10.1038/249275a0 · Cited by 112
Self-citationImmune responses in vitro. ii. mixed leukocyte interaction in a protein‐free medium
Katz‐Heber, E., Peck, A. B., & Click, R. E. (1973) · European Journal of Immunology · doi:10.1002/eji.1830030702 · Cited by 52
Allogeneic Interactions Provide Evidence for a Novel Class of Immunological Reactivity
Lafferty, K. J., Walker, K. Z., Scollay, R. G., & Killby, V. A. A. (1972) · Immunological Reviews · doi:10.1111/j.1600-065x.1972.tb00057.x · Cited by 29
Self-citation
Cited by
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
T-cell regulation by CD28 and CTLA-4
Alegre, M.-L., Frauwirth, K. A., & Thompson, C. B. (2001) · Nature Reviews Immunology · doi:10.1038/35105024 · Cited by 914
van Stipdonk, M. J. B., Lemmens, E. E., & Schoenberger, S. P. (2001) · Nature Immunology · doi:10.1038/87730 · Cited by 841
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836
Negative selection of lymphocytes
Nossal, G. J. V. (1994) · Cell · doi:10.1016/0092-8674(94)90331-x · Cited by 785
Neonatal Tolerance Revisited: Turning on Newborn T Cells with Dendritic Cells
Ridge, J. P., Fuchs, E. J., & Matzinger, P. (1996) · Science · doi:10.1126/science.271.5256.1723 · Cited by 760
Zinkernagel, R. M. (1996) · Science · doi:10.1126/science.271.5246.173 · Cited by 651
Inflammatory signals in dendritic cell activation and the induction of adaptive immunity
Joffre, O., Nolte, M. A., Spörri, R., & Sousa, C. R. E. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00718.x · Cited by 598
SLOANLANCASTER, J. (1994) · Cell · doi:10.1016/0092-8674(94)90080-9 · Cited by 594
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
Zinkernagel, R. M., Ehl, S., Aichele, P., Oehen, S., Kündig, T., & Hengartner, H. (1997) · Immunological Reviews · doi:10.1111/j.1600-065x.1997.tb00969.x · Cited by 489
The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism
Powell, J. D., & Delgoffe, G. M. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.002 · Cited by 486
Immune surveillance against a solid tumor fails because of immunological ignorance
Ochsenbein, A. F., Klenerman, P., Karrer, U., Ludewig, B., Pericin, M., Hengartner, H., & Zinkernagel, R. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2233 · Cited by 453
Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires.
Goodnow, C. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2264 · Cited by 446
Induction of Protective CTL Responses in Newborn Mice by a Murine Retrovirus
Sarzotti, M., Robbins, D. S., & Hoffman, P. M. (1996) · Science · doi:10.1126/science.271.5256.1726 · Cited by 446
mTOR , metabolism, and the regulation of T‐cell differentiation and function
Waickman, A. T., & Powell, J. D. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01152.x · Cited by 420
“Many soluble factors such as the interleukins, interferons, chemokines, the lysophospholipid S1P1, and the adipokine leptin all possess the ability to induce mTOR activity in T cells expressing the appropriate receptors (56–68).”
BackgroundInfluentialLessons learned from the blockade of immune checkpoints in cancer immunotherapy
Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 381
Approaching the Asymptote: 20 Years Later
Medzhitov, R. (2009) · Immunity · doi:10.1016/j.immuni.2009.06.004 · Cited by 373
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
Transgenic Mice and Analysis of B-Cell Tolerance
Goodnow, C. C. (1992) · Annual Review of Immunology · doi:10.1146/annurev.iy.10.040192.002421 · Cited by 359
The role of the PD‐1 pathway in autoimmunity and peripheral tolerance
Fife, B. T., & Pauken, K. E. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05919.x · Cited by 355
At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
Callahan, M. K., & Wolchok, J. D. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212631 · Cited by 348
Role of the Kupffer Cell in Mediating Hepatic Toxicity and Carcinogenesis
Roberts, R. A., Ganey, P. E., Ju, C., Kamendulis, L. M., Rusyn, I., & Klaunig, J. E. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfl173 · Cited by 331
Immunological concepts of vaccine adjuvant activity
Schijns, V. E. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00120-5 · Cited by 330
Self-Tolerance Checkpoints in B Lymphocyte Development
(1995) · Advances in Immunology · doi:10.1016/s0065-2776(08)60633-1 · Cited by 328
Weinkove, R., George, P., Dasyam, N., & McLellan, A. D. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1049 · Cited by 324
Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice
Battegay, M., Moskophidis, D., Rahemtulla, A., Hengartner, H., Mak, T. W., & Zinkernagel, R. M. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4700-4704.1994 · Cited by 320
Transactivation by AP-1 Is a Molecular Target of T Cell Clonal Anergy
Kang, S.-M., Beverly, B., Tran, A.-C., Brorson, K., Schwartz, R. H., & Lenardot, M. J. (1992) · Science · doi:10.1126/science.257.5073.1134 · Cited by 318
POSITIVE VERSUS NEGATIVE SIGNALING BY LYMPHOCYTE ANTIGEN RECEPTORS
Healy, J. I., & Goodnow, C. C. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.645 · Cited by 316
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
Görgün, G., Samur, M. K., Cowens, K. B., Paula, S., Bianchi, G., Anderson, J. E., White, R. E., Singh, A., Ohguchi, H., Suzuki, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0200 · Cited by 309
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
Zhang, Q., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.017 · Cited by 296
ZINKERNAGEL, R. M. (1978) · Immunological Reviews · doi:10.1111/j.1600-065x.1978.tb00264.x · Cited by 291
Is cancer dangerous to the immune system?
Fuchs, E. J., & Matzinger, P. (1996) · Seminars in Immunology · doi:10.1006/smim.1996.0035 · Cited by 289
The discovery of MHC restriction
Zinkernagel, R. M., & Doherty, P. C. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)80008-4 · Cited by 287
An Enigmatic Tail of CD28 Signaling
Boomer, J. S., & Green, J. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002436 · Cited by 283
Azathioprine: old drug, new actions
Maltzman, J. S., & Koretzky, G. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18384 · Cited by 268
Yip, H. C., Karulin, A. Y., Tary-Lehmann, M., Hesse, M. D., Radeke, H., Heeger, P. S., Trezza, R. P., Heinzel, F. P., Forsthuber, T., & Lehmann, P. V. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.7.3942 · Cited by 258
CD80, CD86 and CD40 Provide Accessory Signals in a Multiple‐Step T‐Cell Activation Model
Van Gool, S. W., Vandenberghe, P., Boer, M. D., & Ceuppens, J. L. (1996) · Immunological Reviews · doi:10.1111/j.1600-065x.1996.tb00920.x · Cited by 257
Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease
Attanasio, J., & Wherry, E. J. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.022 · Cited by 256
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Tan, S., Zhang, H., Chai, Y., Song, H., Tong, Z., Wang, Q., Qi, J., Wong, G., Zhu, X., Liu, W. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14369 · Cited by 255
Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
Samaan, M. A., Pavlidis, P., Papa, S., Powell, N., & Irving, P. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.14 · Cited by 100
Metadata
- Authors
- Lafferty, K., & Cunningham, A.
- Venue
- Australian Journal of Experimental Biology and Medical Science
- Publisher
- Wiley
- Published
- 1975-02
- Volume
- 53
- Issue
- 1
- Pages
- 27-42
- ISSN
- 0004-945X (ISSN-L)
- 0818-9641
- OpenAlex
- W1976046966
- Cited by
- 556
- References
- 6
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.